Effect of oral tranexamic acid on macular edema associated with retinal vein occlusion or diabetes

Masayuki Takeyama,1 Fumio Takeuchi,2 Masahiko Gosho,3 Keijiro Sugita,1 Masahiro Zako,4 Masayoshi Iwaki,5 Motohiro Kamei1 1Department of Ophthalmology, Aichi Medical University, Nagakute, 2Department of Biochemistry, Aichi Medical University, Nagakute, 3Department of Clinical Trial and Clinical Epid...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Takeyama M, Takeuchi F, Gosho M, Sugita K, Zako M, Iwaki M, Kamei M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	diabetic macular edema fibrin macular edema plasmin retinal vein occlusion tranexamic acid Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/0c7609b2ec934f428cc463761d8ecb10
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0c7609b2ec934f428cc463761d8ecb10
record_format	dspace
spelling	oai:doaj.org-article:0c7609b2ec934f428cc463761d8ecb102021-12-02T02:58:47ZEffect of oral tranexamic acid on macular edema associated with retinal vein occlusion or diabetes1177-5483https://doaj.org/article/0c7609b2ec934f428cc463761d8ecb102017-12-01T00:00:00Zhttps://www.dovepress.com/effect-of-oral-tranexamic-acid-on-macular-edema-associated-with-retina-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Masayuki Takeyama,1 Fumio Takeuchi,2 Masahiko Gosho,3 Keijiro Sugita,1 Masahiro Zako,4 Masayoshi Iwaki,5 Motohiro Kamei1 1Department of Ophthalmology, Aichi Medical University, Nagakute, 2Department of Biochemistry, Aichi Medical University, Nagakute, 3Department of Clinical Trial and Clinical Epidemiology, Faculty of Medicine, University of Tsukuba, Tsukuba, 4Department of Ophthalmology, Asia Hospital, Seto, 5Department of Ophthalmology, Yokkaichi, Digestive Disease Center, Komono, Japan Purpose: Tranexamic acid (TXA) is a widely used antifibrinolytic agent that can also cause a decrease in vascular permeability. We hypothesized that TXA could improve macular edema (ME) that is caused by an increase in retinal vascular permeability. The aim of this study is to evaluate the efficacy of oral TXA for ME associated with retinal vein occlusion (RVO) or diabetic ME (DME).Patients and methods: Oral TXA (1,500 mg daily for 2 weeks) was administered to patients with persistent ME secondary to RVO (7 eyes) and DME (7 eyes). After 2 weeks (ie, the final day of administration) and 6 weeks (ie, 4 weeks after the final administration), best-corrected visual acuity and central macular thickness (CMT) were measured and compared with baseline. Analyses were performed for RVO and DME cases. No other treatment was performed during the study period.Results: In RVO cases, significant improvement in CMT was found between baseline (467.7±121.4 µm) and 2-week measurements after treatment (428.7±110.5 µm, p=0.024). No significant change was found in CMT between measurements taken at baseline and 6 weeks after treatment. In DME cases, no significant change was found in CMT between measurements taken at baseline and 2 or 6 weeks after treatment. In all analyses of best-corrected visual acuity, no significant change was observed.Conclusion: The results support the hypothesis that plasmin plays a role in the development of ME associated with RVO, and oral TXA administration may be useful as an adjuvant treatment when combined with other agents such as anti-vascular endothelial growth factor. Keywords: diabetic macular edema, fibrin, macular edema, plasmin, retinal vein occlusion, tranexamic acid Takeyama MTakeuchi FGosho MSugita KZako MIwaki MKamei MDove Medical Pressarticlediabetic macular edemafibrinmacular edemaplasminretinal vein occlusiontranexamic acidOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 12, Pp 35-41 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	diabetic macular edema fibrin macular edema plasmin retinal vein occlusion tranexamic acid Ophthalmology RE1-994
spellingShingle	diabetic macular edema fibrin macular edema plasmin retinal vein occlusion tranexamic acid Ophthalmology RE1-994 Takeyama M Takeuchi F Gosho M Sugita K Zako M Iwaki M Kamei M Effect of oral tranexamic acid on macular edema associated with retinal vein occlusion or diabetes
description	Masayuki Takeyama,1 Fumio Takeuchi,2 Masahiko Gosho,3 Keijiro Sugita,1 Masahiro Zako,4 Masayoshi Iwaki,5 Motohiro Kamei1 1Department of Ophthalmology, Aichi Medical University, Nagakute, 2Department of Biochemistry, Aichi Medical University, Nagakute, 3Department of Clinical Trial and Clinical Epidemiology, Faculty of Medicine, University of Tsukuba, Tsukuba, 4Department of Ophthalmology, Asia Hospital, Seto, 5Department of Ophthalmology, Yokkaichi, Digestive Disease Center, Komono, Japan Purpose: Tranexamic acid (TXA) is a widely used antifibrinolytic agent that can also cause a decrease in vascular permeability. We hypothesized that TXA could improve macular edema (ME) that is caused by an increase in retinal vascular permeability. The aim of this study is to evaluate the efficacy of oral TXA for ME associated with retinal vein occlusion (RVO) or diabetic ME (DME).Patients and methods: Oral TXA (1,500 mg daily for 2 weeks) was administered to patients with persistent ME secondary to RVO (7 eyes) and DME (7 eyes). After 2 weeks (ie, the final day of administration) and 6 weeks (ie, 4 weeks after the final administration), best-corrected visual acuity and central macular thickness (CMT) were measured and compared with baseline. Analyses were performed for RVO and DME cases. No other treatment was performed during the study period.Results: In RVO cases, significant improvement in CMT was found between baseline (467.7±121.4 µm) and 2-week measurements after treatment (428.7±110.5 µm, p=0.024). No significant change was found in CMT between measurements taken at baseline and 6 weeks after treatment. In DME cases, no significant change was found in CMT between measurements taken at baseline and 2 or 6 weeks after treatment. In all analyses of best-corrected visual acuity, no significant change was observed.Conclusion: The results support the hypothesis that plasmin plays a role in the development of ME associated with RVO, and oral TXA administration may be useful as an adjuvant treatment when combined with other agents such as anti-vascular endothelial growth factor. Keywords: diabetic macular edema, fibrin, macular edema, plasmin, retinal vein occlusion, tranexamic acid
format	article
author	Takeyama M Takeuchi F Gosho M Sugita K Zako M Iwaki M Kamei M
author_facet	Takeyama M Takeuchi F Gosho M Sugita K Zako M Iwaki M Kamei M
author_sort	Takeyama M
title	Effect of oral tranexamic acid on macular edema associated with retinal vein occlusion or diabetes
title_short	Effect of oral tranexamic acid on macular edema associated with retinal vein occlusion or diabetes
title_full	Effect of oral tranexamic acid on macular edema associated with retinal vein occlusion or diabetes
title_fullStr	Effect of oral tranexamic acid on macular edema associated with retinal vein occlusion or diabetes
title_full_unstemmed	Effect of oral tranexamic acid on macular edema associated with retinal vein occlusion or diabetes
title_sort	effect of oral tranexamic acid on macular edema associated with retinal vein occlusion or diabetes
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/0c7609b2ec934f428cc463761d8ecb10
work_keys_str_mv	AT takeyamam effectoforaltranexamicacidonmacularedemaassociatedwithretinalveinocclusionordiabetes AT takeuchif effectoforaltranexamicacidonmacularedemaassociatedwithretinalveinocclusionordiabetes AT goshom effectoforaltranexamicacidonmacularedemaassociatedwithretinalveinocclusionordiabetes AT sugitak effectoforaltranexamicacidonmacularedemaassociatedwithretinalveinocclusionordiabetes AT zakom effectoforaltranexamicacidonmacularedemaassociatedwithretinalveinocclusionordiabetes AT iwakim effectoforaltranexamicacidonmacularedemaassociatedwithretinalveinocclusionordiabetes AT kameim effectoforaltranexamicacidonmacularedemaassociatedwithretinalveinocclusionordiabetes
_version_	1718402022522224640

Effect of oral tranexamic acid on macular edema associated with retinal vein occlusion or diabetes

Ejemplares similares